Associated Papers
Brief Report: The Effectiveness of Osimertinib in Advanced Nonsmall Cell Lung Cancer Harboring Various EGFR Exon 19 Mutation Variants.
Chang LC et al.
Clinical Lung Cancer, 2025
Patients with Advanced Non-Small Cell Lung Cancer and the EGFR Exon 19 Deletion p.L747 Benefit from Chemotherapy and First-Generation Tyrosine Kinase Inhibitors Compared with Patients with p.E746.
Guan M et al.
Oncotargets and Therapy, 2025
RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants.
Nishino K et al.
Jto Clinical and Research Reports, 2024
Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations.
Grant MJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer.
Huang LT et al.
Lung Cancer (amsterdam, Netherlands), 2022
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
35304574 (PubMed )
Supplement: 41388_2022_2263_MOESM5_ESM.xlsx › Supplementary_Table_4
Comutation and exclusion analysis in human tumors: A tool for cancer biology studies and for rational selection of multitargeted therapeutic approaches.
Ochoa S et al.
Human Mutation, 2019
Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas.
Taniguchi K et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
Select a paper to view details